Purple Biotech Ltd. (PPBT) Stock Forecast
PPBT analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 1 analysts
- Price target
- $17.00 average of analyst targets
- Upside to target
- +1,391.2% from the latest close
- Next earnings
- November 13, 2026 EPS estimate $-2.88
- 52-week range
- $1.14 – $10.60
PPBT analyst ratings
1 analystsNumber of analysts at each rating.
PPBT price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
PPBT earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$2.88 | −$2.88 | −$2.88 | $2.90 | −199.3% | 1 |
| Current fiscal year (2026) | −$5.73 | −$5.73 | −$5.73 | −$8.23 | +30.4% | 1 |
| Next fiscal year (2027) | −$1.01 | −$1.01 | −$1.01 | −$5.73 | +82.4% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
PPBT revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 1 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 1 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 1 |
PPBT EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
PPBT EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.42 | −$1.73 | −$1.73 | −$1.73 | −$2.88 | +585.7% | 0 up · 1 down |
| Current fiscal year (2026) | −$1.65 | −$5.31 | −$5.31 | −$5.31 | −$5.73 | +247.3% | 0 up · 1 down |
| Next fiscal year (2027) | −$0.64 | −$0.88 | −$0.88 | −$0.88 | −$1.01 | +57.8% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
PPBT earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; PPBT beat in 4 of 11.
What analysts expect from PPBT
1 analysts cover Purple Biotech; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $17.00, 1,391.2% above the latest close of $1.14. Analysts expect earnings of −$5.73 per share for 2026, +30.4% from a year earlier. For 2027 the average estimate is −$1.01 per share. Purple Biotech beat the EPS estimate in 4 of the last 11 quarters.
Related: PPBT income statement, PPBT key metrics, PPBT chart. See the PPBT stock overview for the latest quote and news.
PPBT forecast FAQ
What is Purple Biotech's price target?
The average analyst price target for Purple Biotech is $17.00, 1,391.2% above the latest close of $1.14.
Is Purple Biotech a buy, hold or sell?
Of 1 analysts covering Purple Biotech, 1 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Purple Biotech's EPS forecast?
Analysts forecast −$5.73 per share for 2026 (range −$5.73 to −$5.73); for 2027 the estimate is −$1.01.
When does Purple Biotech report earnings?
Purple Biotech is expected to report results for the quarter ending September 30, 2026 on November 13, 2026; the EPS estimate is $-2.88.
Does Purple Biotech usually beat earnings estimates?
Purple Biotech reported EPS at or above the analyst estimate in 4 of the last 11 quarters.